CELU Quote, Financials, Valuation and Earnings

NovaBay Pharmaceuticals, Inc. has a net margin of -436.72% compared to Celularity, Inc.'s net margin of -255.85%. Celularity, Inc.'s return on equity of -1606.74% beat NovaBay Pharmaceuticals, Inc.'s return on equity of -306.03%.

Celularity, Inc. has a consensus price target of --, signalling upside risk potential of 1765.67%. On the other hand NovaBay Pharmaceuticals, Inc. has an analysts' consensus of $0.85 which suggests that it could fall by -82.47%. Given that Celularity, Inc. has higher upside potential than NovaBay Pharmaceuticals, Inc., analysts believe Celularity, Inc. is more attractive than NovaBay Pharmaceuticals, Inc..

Celularity, Inc. has a beta of 0.772, which suggesting that the stock is 22.78% less volatile than S&P 500. In comparison NovaBay Pharmaceuticals, Inc. has a beta of 0.569, suggesting its less volatile than the S&P 500 by 43.103%.

Celularity, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. NovaBay Pharmaceuticals, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.80 per share. Celularity, Inc. pays -- of its earnings as a dividend. NovaBay Pharmaceuticals, Inc. pays out -- of its earnings as a dividend.

Celularity, Inc. quarterly revenues are $5.3M, which are larger than NovaBay Pharmaceuticals, Inc. quarterly revenues of $521K. Celularity, Inc.'s net income of -$23.1M is lower than NovaBay Pharmaceuticals, Inc.'s net income of -$1.3M. Notably, Celularity, Inc.'s price-to-earnings ratio is -- while NovaBay Pharmaceuticals, Inc.'s PE ratio is 8.15x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Celularity, Inc. is 0.79x versus 9.42x for NovaBay Pharmaceuticals, Inc.. Usually stocks with elevated PS ratios are considered overvalued.

Organogenesis Holdings, Inc. has a net margin of -436.72% compared to Celularity, Inc.'s net margin of 14.3%. Celularity, Inc.'s return on equity of -1606.74% beat Organogenesis Holdings, Inc.'s return on equity of 0.28%.

Celularity, Inc. has a consensus price target of --, signalling upside risk potential of 1765.67%. On the other hand Organogenesis Holdings, Inc. has an analysts' consensus of $8.50 which suggests that it could grow by 61.14%. Given that Celularity, Inc. has higher upside potential than Organogenesis Holdings, Inc., analysts believe Celularity, Inc. is more attractive than Organogenesis Holdings, Inc..

Celularity, Inc. has a beta of 0.772, which suggesting that the stock is 22.78% less volatile than S&P 500. In comparison Organogenesis Holdings, Inc. has a beta of 1.471, suggesting its more volatile than the S&P 500 by 47.143%.

Celularity, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Organogenesis Holdings, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Celularity, Inc. pays -- of its earnings as a dividend. Organogenesis Holdings, Inc. pays out -- of its earnings as a dividend.

Celularity, Inc. quarterly revenues are $5.3M, which are smaller than Organogenesis Holdings, Inc. quarterly revenues of $150.9M. Celularity, Inc.'s net income of -$23.1M is lower than Organogenesis Holdings, Inc.'s net income of $21.6M. Notably, Celularity, Inc.'s price-to-earnings ratio is -- while Organogenesis Holdings, Inc.'s PE ratio is 70.39x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Celularity, Inc. is 0.79x versus 1.46x for Organogenesis Holdings, Inc.. Usually stocks with elevated PS ratios are considered overvalued.

Palatin Technologies has a net margin of -436.72% compared to Celularity, Inc.'s net margin of --. Celularity, Inc.'s return on equity of -1606.74% beat Palatin Technologies's return on equity of --.

Celularity, Inc. has a consensus price target of --, signalling upside risk potential of 1765.67%. On the other hand Palatin Technologies has an analysts' consensus of -- which suggests that it could grow by 7338.9%. Given that Palatin Technologies has higher upside potential than Celularity, Inc., analysts believe Palatin Technologies is more attractive than Celularity, Inc..

Celularity, Inc. has a beta of 0.772, which suggesting that the stock is 22.78% less volatile than S&P 500. In comparison Palatin Technologies has a beta of 0.939, suggesting its less volatile than the S&P 500 by 6.103%.

Celularity, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Palatin Technologies offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Celularity, Inc. pays -- of its earnings as a dividend. Palatin Technologies pays out -- of its earnings as a dividend.

Celularity, Inc. quarterly revenues are $5.3M, which are larger than Palatin Technologies quarterly revenues of --. Celularity, Inc.'s net income of -$23.1M is higher than Palatin Technologies's net income of --. Notably, Celularity, Inc.'s price-to-earnings ratio is -- while Palatin Technologies's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Celularity, Inc. is 0.79x versus -- for Palatin Technologies. Usually stocks with elevated PS ratios are considered overvalued.

Theriva Biologics, Inc. has a net margin of -436.72% compared to Celularity, Inc.'s net margin of --. Celularity, Inc.'s return on equity of -1606.74% beat Theriva Biologics, Inc.'s return on equity of -171.04%.

Celularity, Inc. has a consensus price target of --, signalling upside risk potential of 1765.67%. On the other hand Theriva Biologics, Inc. has an analysts' consensus of $7.00 which suggests that it could grow by 3559.17%. Given that Theriva Biologics, Inc. has higher upside potential than Celularity, Inc., analysts believe Theriva Biologics, Inc. is more attractive than Celularity, Inc..

Celularity, Inc. has a beta of 0.772, which suggesting that the stock is 22.78% less volatile than S&P 500. In comparison Theriva Biologics, Inc. has a beta of 0.342, suggesting its less volatile than the S&P 500 by 65.818%.

Celularity, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Theriva Biologics, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Celularity, Inc. pays -- of its earnings as a dividend. Theriva Biologics, Inc. pays out -- of its earnings as a dividend.

Celularity, Inc. quarterly revenues are $5.3M, which are larger than Theriva Biologics, Inc. quarterly revenues of --. Celularity, Inc.'s net income of -$23.1M is lower than Theriva Biologics, Inc.'s net income of -$4.4M. Notably, Celularity, Inc.'s price-to-earnings ratio is -- while Theriva Biologics, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Celularity, Inc. is 0.79x versus 0.33x for Theriva Biologics, Inc.. Usually stocks with elevated PS ratios are considered overvalued.